Cancer

Multiple Myeloma study CC-220

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Trial overview

Disease

Myeloma

Topic

Multiple Myeloma study CC-220

Sponsor

Description

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma

Trial status

Recruitment closed

Location

Principle Investigator

Dr Karthik Ramasamy

MBBS, PhD, FRCP, FRCPath

Haematologist

Oxford